Albany Molecular Research, Inc. Wtih Sanofi-Aventis (Massachusetts) Files Motion for Preliminary Injunction Prohibiting Dr. Reddy's Laboratories, Inc.'s from Distributing Generic Allegra-D(R) 24

Published: Mar 23, 2010

ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) today announced that it along with sanofi-aventis U.S. LLC, has filed a motion for a preliminary injunction in the United States District Court for the District of New Jersey seeking to enjoin Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (Dr. Reddy’s) from the commercial distribution of generic versions of Allegra-D® 24 Hour (fexofenadine HCl 180 mg and pseudoephedrine HCl 240 mg) Extended-Release Tablets in the U.S. This action is in response to the March 17, 2010 approval of Dr. Reddy’s generic version of Allegra-D® 24 Hour by the FDA.

Back to news